Abstract
Inhibitors of the proto-oncogene MET are showing promise as anti-angiogenics. Shahneed Sandhu (Sutton, UK) presented findings from a phase 1 trial of the oral MET inhibitor, ARQ197, in 29 patients with advanced solid tumours. The drug was well tolerated, with only three patients exhibiting dose-limiting toxicities, and a phase 2 dose of 300 mg twice daily was recommended. MRI of tumours in 12 patients showed a reduction in tumour permeability sustained over 56 treatment days, suggesting an anti-angiogenic response.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
